Skip to main content

BRIEF RESEARCH REPORT article

Front. Oncol.
Sec. Cardio-Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1483918

Statin Prescription Disparities in Patients with Breast Cancer and Diabetes for Primary Cardiovascular Disease Prevention

Provisionally accepted
Alicia B. Yang Alicia B. Yang Grace Mhango Grace Mhango Chung Yin Kong Chung Yin Kong Jenny J. Lin Jenny J. Lin Juan P. Wisnivesky Juan P. Wisnivesky Amanda Leiter Amanda Leiter *
  • Icahn School of Medicine at Mount Sinai, New York, United States

The final, formatted version of the article will be published soon.

    Background: This brief report examines statin prescription trends for primary cardiovascular disease (CVD) prevention in breast cancer (BC) survivors with diabetes, a large population at particularly high CVD risk. Methods: A population-based, retrospective cohort study was conducted using Surveillance, Epidemiology and End Results (SEER) cancer registry data linked to Medicare claims. We identified women with preexisting diabetes who were diagnosed with stage 0-III primary BC between 2008-17 without preexisting CVD. We assessed statin prescription rates over time and also examined differences in statin prescription rates according to patient sociodemographic characteristics. Using a multivariate logistic regression adjusting for socioedemographic and clinical variables, independent predictors of statin prescription were identified. Results: Of 8,423 BC patients with diabetes without preexisting CVD, 5,698 (68%) had a statin prescription. Statin prescriptions increased over time (BC diagnosis year 2008-09: 65%, 2010-11: 67%, 2012-13: 66%, 2014-15: 69%, 2016-17: 70%, p=0.01) and differed by age (66-69: 66%, 70-74: 70%, 75-79: 69%, ≥80: 65%; p<0.01) and race (White: 68%, Black: 62%, Latinx: 66%, Other: 72%; p<0.01). In a multivariate analysis, race (Black vs. White: OR 0.80, 95% CI: 0.68-0.95) remained a predictor of statin prescription. Conclusion: In older early-stage BC survivors, statin prescriptions increased over time and varied by age, race, and BC stage. These findings can potentially inform strategies to improve guideline-concordant statin prescriptions in a group at high risk for CVD and reduce disparities.

    Keywords: breast cancer, diabetes, statin, cardiovascular prevention, disparities (health racial), cancer survivor

    Received: 20 Aug 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Yang, Mhango, Kong, Lin, Wisnivesky and Leiter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Amanda Leiter, Icahn School of Medicine at Mount Sinai, New York, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.